Learn more

BATU BIOLOGICS INC

Overview
  • Total Patents
    36
  • GoodIP Patent Rank
    43,673
  • Filing trend
    0.0%
About

BATU BIOLOGICS INC has a total of 36 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2016. It filed its patents most often in United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are TIANJIN RINGPU BIOTECHNOLOGY CO LTD, YEBIO BIOENG CO LTD QINGDAO and BEIJING MINHAI BIOTECHNOLOGY CO LTD.

Patent filings in countries

World map showing BATU BIOLOGICS INCs patent filings in countries

Patent filings per year

Chart showing BATU BIOLOGICS INCs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Wagner Samuel C 34
#2 Ichim Thomas E 31
#3 Minev Boris 6
#4 Kesari Santosh 6
#5 Bogin Vladimir 4
#6 Ichim Thomas 4
#7 Patel Amit N 3
#8 Wagner Samuel 2
#9 Szymanski Julia S 2
#10 Kim Andy J 1

Latest patents

Publication Filing date Title
US2019282641A1 Generation of Tumor Endothelium Specific Viruses
US2020297829A1 Integrative Immunotherapy for Cancer Treatment
US2019255127A1 Augmentation of Oncolytic Viral Efficacy through Immunological Targeting Tumor Endothelial Cells
US2019239937A1 Augmentation of Abscopal Effect of Cryotherapy and other Tumor Cell Death by Anti-angiogenic and Anti-tumor Vaccination
US2019224292A1 Methods of Augmenting Tumor Vaccine Efficacy through Endothelial Targeting
US2019201511A1 Placental Based Contraceptive Vaccine
US2019117703A1 Immunological treatment of liver failure
US2019161798A1 Selection of Donors for Generation of Anti-Angiogenic Vaccine Compositions Including ValloVax
US2018264049A1 Immunotherapy of Aberrant Ocular Angiogenesis by Placental Vaccination
US2018264096A1 Prophylactic Vaccine to Tumor Angiogenesis
US2018110847A1 Immunotherapy of Cancer by Induction of Immunologically-Mediated Selective Killing of Tumor Vasculature Using Modified Endothelial Cells and Progenitors Thereof
US2018280444A1 Nanoparticle based tumor endothelial targeting vaccine
US2017348388A1 Adjuvants useful for stimulation of immunity to tumor endothelial cells
US2017348361A1 Probiotic augmentation of anti-tumor endothelium immune responses
US2017216354A1 Clinically useful non-antigen pulsed dendritic cells
US2017107510A1 Dna nanoparticle based checkpoint inhibitors
US2017100438A1 Treatment of glioma by anti-angiogenic active immunization for direct tumor inhibition and augmentation of chemotherapy, immunotherapy and radiotherapy efficacy
US2017100468A1 Amplification of epitope specific personalized anti-angiogenic immune responses
US2017152506A1 Inactivation of lymphocyte immunological checkpoints by gene editing
US2017196951A1 Polyvalent anti-tumor fibroblast vaccine